Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUALIFY: Qishen Yiqi Dripping Pills in Chronic Heart Failure
NCT07687186Phase 3Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) comparing Qishen Yiqi Dripping Pills with Placebo (2 arms). Primary endpoint: 6-minute Walk Distance at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
qishen yiqi dripping pills
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT07687186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687186.